News – Phase 1 Clinical Studies Planning Well Advanced
PresSura Neuro is pleased to report that it has progressed its innovative compound, EU-C-001, for the treatment of Intracranial Pressure (ICP) in Traumatic Brain Injury (TBI), as well as long term outcome after Concussion (Post Concussion Syndrome (PCS)) and Chronic Traumatic Encephalopathy (CTE). The manufacturing of the drug substance is well advanced and preclinical studies with the drug are in progress.
PresSure has commenced preparation for a Phase 1 safety study for EU-C-001, for the treatment of TBI, concussion/CTE. (20 March 2015).
PresSura's Scientists have discovered two distinct mechanisms that are involved in either the development of PCS and Chronic Traumatic Encephalopathy (CTE) after repeated concussion as well the increase of Intracranial Pressure following Traumatic Brain Injury (TBI).
PressSura's drug showed promising activity in animal models of both concussion / CTE and ICP following a TBI.
To find out more about what we do, browse the rest of our site or contact us at email@example.com